Regression of structural cardiovascular changes by antihypertensive therapy

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Research

Background:

• Left ventricular (LV) hypertrophy is a cardiac adaptation to chronic pressure overload.
• Spontaneously hypertensive rats (SHR) serve as a model for genetically determined hypertension.

Purpose of the Study:

• To investigate the effects of antihypertensive agents on cardiac hypertrophy in SHR.
• To explore drug-specific modulations and timing of therapy on cardiac structure and function.

Main Methods:

• Treatment of SHR with various antihypertensive agents (e.g., hydralazine, captopril, metoprolol, nifedipine).
• Assessment of blood pressure normalization, LV hypertrophy, collagen concentration, and LV function.
• Comparison of single versus combined drug therapies and treatment timing (preventive vs. established hypertrophy).

Main Results:

• Long-term blood pressure normalization effectively controlled cardiac hypertrophy.
• Combined therapy (metoprolol + hydralazine) resulted in lower LV hypertrophy than single hydralazine, despite equal blood pressure reduction.
• Preventive therapy prevented cardiac dysfunction; therapy for established hypertrophy showed varied effects on collagen concentration.
• LV function improved with antihypertensive therapy in cases of LV dilatation and increased systolic wall stress, but not in concentric hypertrophy with normal wall stress.

Conclusions:

• Antihypertensive therapy is crucial for managing cardiac hypertrophy and preventing cardiac dysfunction in hypertensive models.
• The choice of agent and timing of intervention significantly impact therapeutic outcomes.
• LV systolic unloading via antihypertensive therapy can improve cardiac function in specific conditions like LV dilatation.